Synthetics Biologics appoints 4 gastroenterologists to IBS clinical advisory board

Biotechnology company Synthetics Biologics has expanded its Irritable Bowel Syndrome Clinical Advisory Board with the appointment of four GI physicians.

The clinical advisory board, chaired by Cedars Sinai Medical Center GI Motility Program and Laboratory Director Mark Pimentel, MD, is designed to support the development of IBS treatment SYN-010.

The new advisory board members include:

•    William Chey, MD, director of the GI Physiology Laboratory and co-director of the Michigan Bowel Control Program at the University of Michigan in Ann Arbor
•    Gail M. Corner, MD, a board-certified gastroenterologist and hepatologist with experience in the pharmaceutical industry
•    Anthony J. Lembo, MD, associate professor of medicine at Harvard Medical School and director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center, both in Boston
•    Philip Schoenfeld, MD, MSED, MSc, professor of medicine at the University of Michigan School of Medicine and director of the university's Gastrointestinal Epidemiology Training Program

More articles on gastroenterology:
11 statistics on gastroenterologists & payer relationships
FDA approves combination drug Harvoni for HCV
Metropolitan Gastroenterology Group to expand outpatient office

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast